Logo

2013 Vol.31, N°4 - Suppl.78 - Table of contents

Possible Discontinuation of Therapies in Inflammatory Rheumatic DiseasesTitle: Possible Discontinuation of Therapies in Inflammatory Rheumatic Diseases

Guest Editors: T. Pincus, J. Braun, A. Kavanaugh, J.S. Smolen

Purchase all articles

PageArticle - [Author(s)]PDFAbs.
Continuing Medical Education Activity

CER6998
2013,31,4,Suppl.78
Pg. 0000

Possible discontinuation of therapies in inflammatory rheumatic diseases
T. Pincus, J. Braun, A. Kavanaugh, J. Smolen › Free to View
Rheumatology ArticleRheumatology Abstract
Introduction

CER6956
2013,31,4,Suppl.78
Pg. 0001-0003

Possible discontinuation of therapies in inflammatory rheumatic diseases – as with initiation of therapies, a shared decision between patient and rheumatologist
T. Pincus, J. Braun, A. Kavanaugh, J. Smolen › Free to View
Rheumatology ArticleRheumatology Abstract
 

CER6886
2013,31,4,Suppl.78
Pg. 0004-0008

Can we discontinue synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis?
I. Scott, G. Kingsley, D. Scott › Free to View
Rheumatology ArticleRheumatology Abstract
 

CER6938
2013,31,4,Suppl.78
Pg. 0009-0013

The role of low-dose glucocorticoids for rheumatoid arthritis in the biologic era
R. Caporali, C. Scirè, M. Todoerti, C. Montecucco › Free to View
Rheumatology ArticleRheumatology Abstract
Rheumatoid arthritis

CER6887
2013,31,4,Suppl.78
Pg. 0014-0018

The BeSt way of withdrawing biologic agents
C. Allaart, W. Lems, T. Huizinga › Free to View
Rheumatology ArticleRheumatology Abstract
 

CER6888
2013,31,4,Suppl.78
Pg. 0019-0021

The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trials
A. Kavanaugh, J. Smolen › Free to View
Rheumatology ArticleRheumatology Abstract
 

CER6798
2013,31,4,Suppl.78
Pg. 0022-0027

Discontinuation of biologics in patients with rheumatoid arthritis
Y. Tanaka, S. Hirata, B. Saleem, P. Emery › Free to View
Rheumatology ArticleRheumatology Abstract
 

CER6890
2013,31,4,Suppl.78
Pg. 0028-0032

Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities
K. Yoshida, H. Radner, A. Kavanaugh, Y. Sung, S. Bae, M. Kishimoto, K. Matsui, M. Okada, S. Tohma, M. Weinblatt, D. Solomon › Free to View
Rheumatology ArticleRheumatology Abstract
Spondyloarthropathies (SpA)

CER6891
2013,31,4,Suppl.78
Pg. 0033-0036

Remission and possible discontinuation of biological therapy in axial spondyloarthritis
J. Braun, J. Sieper › Free to View
Rheumatology ArticleRheumatology Abstract
 

CER6893
2013,31,4,Suppl.78
Pg. 0037-0042

Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease
I. Song, H. Haibel, D. Poddubnyy, J. Braun, J. Sieper › Free to View
Rheumatology ArticleRheumatology Abstract
 

CER6901
2013,31,4,Suppl.78
Pg. 0043-0046

Withdrawal of biologic therapy in axial spondyloarthritis: the experience in established disease
X. Baraliakos, U. Kiltz, F. Heldmann, J. Sieper, J. Braun › Free to View
Rheumatology ArticleRheumatology Abstract
 

CER6902
2013,31,4,Suppl.78
Pg. 0047-0050

Withdrawal of medical therapies in axial spondyloarthritis: what would be the optimal trial design?
U. Kiltz, X. Baraliakos, J. Braun, D. van der Heijde › Free to View
Rheumatology ArticleRheumatology Abstract
Psoriatic arthritis (PsA)

CER6903
2013,31,4,Suppl.78
Pg. 0051-0053

Can biologic therapies be withdrawn or tapered in psoriatic arthritis?
A. Moverley, L. Coates, P. Helliwell › Free to View
Rheumatology ArticleRheumatology Abstract
 

CER6904
2013,31,4,Suppl.78
Pg. 0054-0058

Can traditional disease-modifying anti-rheumatic drugs be withdrawn or tapered in psoriatic arthritis?
E. Lubrano, E. Soriano, O. FitzGerald › Free to View
Rheumatology ArticleRheumatology Abstract
 

CER6916
2013,31,4,Suppl.78
Pg. 0059-0062

Is reduction or discontinuation of therapy an acceptable possibility in psoriatic arthritis?
P. Mease › Free to View
Rheumatology ArticleRheumatology Abstract
 

CER6937
2013,31,4,Suppl.78
Pg. 0063-0070

Continuous versus intermittent therapy for moderate-to-severe psoriasis
M. Ramirez-Fort, A. Levin, S. Au, A. Gottlieb › Free to View
Rheumatology ArticleRheumatology Abstract
Systemic lupus erythematosus

CER6954
2013,31,4,Suppl.78
Pg. 0071-0074

Withdrawal of therapy in non-renal systemic lupus erythematosus: is this an achievable goal?
M. Mosca, C. Tani, M. Aringer › Free to View
Rheumatology ArticleRheumatology Abstract
 

CER6818
2013,31,4,Suppl.78
Pg. 0075-0081

What happens after complete withdrawal of therapy in patients with lupus nephritis
G. Moroni, S. Longhi, E. Giglio, P. Messa, C. Ponticelli › Free to View
Rheumatology ArticleRheumatology Abstract
 

CER6955
2013,31,4,Suppl.78
Pg. 0082-0085

New drugs in systemic lupus erythematosus: when to start and when to stop
M. Mosca, R. van Vollenhoven › Free to View
Rheumatology ArticleRheumatology Abstract
Vasculitis

CER6930
2013,31,4,Suppl.78
Pg. 0086-0092

Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis
F. Muratore, N. Pipitone, G. Hunder, C. Salvarani › Free to View
Rheumatology ArticleRheumatology Abstract
 

CER6917
2013,31,4,Suppl.78
Pg. 0093-0097

Discontinuation of therapies in vasculitis
R. Luqmani › Free to View
Rheumatology ArticleRheumatology Abstract
Juvenile arthritis

CER6905
2013,31,4,Suppl.78
Pg. 0098-0101

Possible discontinuation of therapies after clinical remission in juvenile idiopathic arthritis
S. Verazza, G. Negro, D. Marafon, A. Consolaro, A. Martini, A. Ravelli › Free to View
Rheumatology ArticleRheumatology Abstract
Continuing Medical Education Activity

CER7017
2013,31,4,Suppl.78
Pg. 0102-0107

Possible Discontinuation of Therapies in Inflammatory Rheumatic Diseases: CME activity
No Author › Free to View
Rheumatology ArticleRheumatology Abstract